Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Melanoma · Unresectable Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Angeles Clinic at Cedars Sinai, Los Angeles, California, United States
Contact: Principal Investigator (Inderjit Mehmi, MD)Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Ryan Sullivan, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Stephen Hodi, MD)NYU Langone Health, New York, New York, United States
Contact: Principal Investigator (Janice Mehnert, MD)
Study leads
Janice Mehnert, MD
Principal Investigator
NYU Langone Health